Method of treatment of diabetes and/or obesity with reduced nausea side effect

• US 8,039,432 B2
• Filed: 11/09/2006
• Issued: 10/18/2011
• Est. Priority Date: 11/09/2005
• Status: Expired due to Fees

• Current Assignee: ConjuChem LLC (Colabor Group, Inc.)
• Original Assignee: ConjuChem LLC (Colabor Group, Inc.)
• Inventors: Bridon, Dominique P., Thibaudeau, Karen, Castaigne, Jean-Paul
• Primary Examiner(s): Allen; Marianne P
• Application Number:
  US11/595,576
• Publication Number:
  US 20070207958A1
• Time in Patent Office: 1,804 Days
• Field of Search: None
• US Class Current: 514/6.7
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 47/643 Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
• CPC Class Codes: A61P 1/08 for nausea, cinetosis or vertigo; Antiemetics
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.

Claims

1. A method of administering an exendin-4 peptide to a nausea-sensitive subject comprising subcutaneously administering to said nausea-sensitive subject the exendin-4 peptide conjugated to albumin, wherein the administration of the conjugated exendin-4 peptide to an animal reduces nausea compared to administration of the unconjugated exendin-4 peptide to the animal, and wherein the conjugated exendin-4 peptide is a conjugate (SEQ ID NO:

28) according to the following formula;

2. The method of claim 1 further comprising the step of selecting the nausea-sensitive subject prior to administering said exendin-4 peptide conjugated to albumin.

3. The method of claim 1 wherein said nausea-sensitive subject is nausea sensitive as a result of having been administered an unconjugated exendin-4 peptide, wherein said exendin-4 peptide is SEQ ID NO:

12.

4. The method of claim 1 wherein said administering of the conjugated exendin-4 peptide prevents nausea in the subject.

5. The method of claim 1 which comprises administering the conjugated exendin-4 peptide in an amount between 1000 and 4000 μ

g, and wherein the nausea-sensitive subject is a human.

6. The method of claim 1 which comprises administering the conjugated exendin-4 peptide in an amount between 1250 and 3750 μ

g, and wherein the nausea-sensitive subject is a human.

7. The method of claim 1 which comprises administering the conjugated exendin-4 peptide in an amount between 1250 and 2500 μ

g, and wherein the nausea-sensitive subject is a human.

8. The method of claim 1 which comprises administering the conjugated exendin-4 peptide in an amount of 1250 μ

g, and wherein the nausea-sensitive subject is a human.

9. The method of claim 1 which comprises administering the conjugated exendin-4 peptide in an amount of 2500 μ

g, and wherein the nausea-sensitive subject is a human.

10. The method of claim 1 which comprises administering the conjugated exendin-4 peptide in an amount of 3750 μ

g, and wherein the nausea-sensitive subject is a human.

11. The method of claim 1 wherein said administering of the conjugated exendin-4 peptide is in an amount effective to treat a disease or disorder that is characterized by the fact that it is treatable by the action of said unconjugated exendin-4 peptide.

12. The method of claim 11 wherein the disease or disorder is obesity or diabetes.

13. The method of claim 12 wherein the disease or disorder is obesity.

14. The method of claim 12 wherein the disease or disorder is diabetes.

15. The method of claim 14 wherein the disease or disorder is type II diabetes.

16. The method of claim 1 wherein the subject is human.

17. The method of claim 1 wherein the human serum albumin is recombinant human serum albumin.

18. The method of claim 1 wherein the conjugated exendin-4 peptide is purified.

19. The method of claim 1 which comprises administering the conjugated exendin-4 peptide in an amount of 1500 μ

g, and wherein the nausea-sensitive subject is a human.

20. The method of claim 1 which comprises administering the conjugated exendin-4 peptide in an amount of 2000 μ

g, and wherein the nausea-sensitive subject is a human.

21. The method of claim 1 which comprises administering the conjugated exendin-4 peptide in an amount of 3000 μ

g, and wherein the nausea-sensitive subject is a human.

22. The method of claim 1, wherein the subject is experiencing nausea at the time of said administering.

28. The method of any one of claims 1, 23 and 24, wherein the subject is a human, and wherein the conjugated exendin-4 peptide is purified.

23. A method of administering an exendin-4 peptide to a subject comprising (a) selecting a nausea sensitive subject having a disease or disorder treatable with the exendin-4 peptide;

and (b) subcutaneously administering to the subject the exendin-4 peptide conjugated to albumin wherein administration of the conjugated exendin-4 peptide to an animal reduces nausea compared to administration of the unconjugated exendin-4 peptide to the animal, and wherein the conjugated exendin-4 peptide is a conjugate (SEQ ID NO;

28) according to the following formula;

24. A method for the treatment of diabetes or obesity in a subject, comprising:

(a) selecting a nausea-sensitive subject in need of said treatment, and

(b) subcutaneously administering an exendin-4 peptide conjugated to albumin to the selected subject,

wherein the administration of the conjugated exendin-4 peptide to an animal provides a reduced nausea side effect compared to the administration of the exendin-4 peptide alone to the animal, and wherein the conjugated exendin-4 peptide is a conjugate (SEQ ID NO;

28) according to the following formula;

25. The method of claim 24, wherein the disease is diabetes.

26. The method of claim 24, wherein the disease is obesity.

27. The method of claim 24, wherein the human serum albumin is recombinant human serum albumin.